ChenGuang Biotech Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

ChenGuang Biotech Group wird ein jährliches Gewinn- und Umsatzwachstum von 54.6% bzw. 7.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 54.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.1% betragen.

Wichtige Informationen

54.6%

Wachstumsrate der Gewinne

54.3%

EPS-Wachstumsrate

Food Gewinnwachstum	22.3%
Wachstumsrate der Einnahmen	7.8%
Zukünftige Eigenkapitalrendite	11.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	28 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21

Recent updates

A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb

Oct 08

ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively

Sep 30

Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing

May 13

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Apr 25

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21

Gewinn- und Umsatzwachstumsprognosen

SZSE:300138 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8,273	497	N/A	N/A	3
12/31/2025	7,402	368	N/A	N/A	4
12/31/2024	6,999	154	N/A	N/A	1
9/30/2024	6,927	150	N/A	N/A	N/A
6/30/2024	6,694	287	N/A	N/A	N/A
3/31/2024	6,786	389	N/A	N/A	N/A
12/31/2023	6,872	486	N/A	N/A	N/A
9/30/2023	6,669	496	-146	33	N/A
6/30/2023	6,737	492	286	453	N/A
3/31/2023	6,529	462	489	627	N/A
12/31/2022	6,296	434	559	735	N/A
9/30/2022	6,465	429	291	478	N/A
6/30/2022	6,002	403	36	244	N/A
3/31/2022	5,446	380	-587	-329	N/A
12/31/2021	4,874	352	-217	64	N/A
9/30/2021	4,410	322	59	407	N/A
6/30/2021	4,186	304	46	455	N/A
3/31/2021	4,188	285	225	715	N/A
1/1/2021	3,913	268	93	529	N/A
9/30/2020	3,667	252	272	667	N/A
6/30/2020	3,481	235	36	405	N/A
3/31/2020	3,288	206	-170	88	N/A
12/31/2019	3,265	194	-290	-24	N/A
9/30/2019	3,226	165	70	292	N/A
6/30/2019	3,378	162	29	207	N/A
3/31/2019	3,139	146	-196	-37	N/A
1/1/2019	3,063	145	-196	-56	N/A
9/30/2018	2,799	155	-536	-381	N/A
6/30/2018	2,779	159	N/A	-283	N/A
3/31/2018	2,807	155	N/A	-176	N/A
12/31/2017	2,772	143	N/A	-146	N/A
9/30/2017	2,780	129	N/A	-55	N/A
6/30/2017	2,384	120	N/A	-292	N/A
3/31/2017	2,259	111	N/A	-354	N/A
12/31/2016	2,141	92	N/A	-322	N/A
9/30/2016	1,824	99	N/A	125	N/A
6/30/2016	1,636	79	N/A	156	N/A
3/31/2016	1,474	80	N/A	44	N/A
12/31/2015	1,268	69	N/A	-65	N/A
9/30/2015	1,246	59	N/A	54	N/A
6/30/2015	1,287	57	N/A	178	N/A
3/31/2015	1,205	24	N/A	209	N/A
12/31/2014	1,207	22	N/A	273	N/A
9/30/2014	1,238	21	N/A	266	N/A
6/30/2014	1,174	4	N/A	117	N/A
3/31/2014	1,131	3	N/A	38	N/A
12/31/2013	1,186	10	N/A	-36	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 300138Das prognostizierte Gewinnwachstum (54.6% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 300138Die Erträge des Unternehmens (54.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.1% pro Jahr).

Hohe Wachstumserträge: 300138Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 300138Die Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 300138Die Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 300138Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.1%).

ChenGuang Biotech Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 19%

Price target decreased by 7.3% to CN¥17.31

Consensus EPS estimates fall by 15%, revenue upgraded

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Price target decreased by 8.0% to CN¥20.43

Consensus revenue estimates increase by 11%

Recent updates

Third quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.19 profit in 3Q 2023)

Investor sentiment improves as stock rises 15%

A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 19%

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.31 in 2Q 2023)

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

ChenGuang Biotech Group Co., Ltd. Approves Cash Dividend on A Shares for the Year 2023, Payable on 13 June 2024

Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing

ChenGuang Biotech Group Co., Ltd. Approves Cash Dividend for the Year 2023

Price target decreased by 7.3% to CN¥17.31

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Consensus EPS estimates fall by 15%, revenue upgraded

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

ChenGuang Biotech Group Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: CN¥0.91 (vs CN¥0.81 in FY 2022)

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on November 17, 2023.

Price target decreased by 8.0% to CN¥20.43

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2022)

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

ChenGuang Biotech Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 17 May 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.82 (vs CN¥0.67 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Chenguang Biotech Group Co., Ltd. Announces 2021 Final Cash Dividend Proposal on A Shares, Payable on 1 June 2022

Consensus revenue estimates increase by 11%

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chenguang Biotech Group Co., Ltd. Approves Cash Dividend

Full year 2021 earnings: EPS and revenues exceed analyst expectations

ChenGuang Biotech Group Co., Ltd. Announces Final Dividend For the Year 2021

Price target increased to CN¥20.80

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Revenue and earnings beat expectations

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: CN¥15.29

Investor sentiment deteriorated over the past week

New 90-day high: CN¥19.53

Market bids up stock over the past week

New 90-day high: CN¥18.18

Third quarter earnings released

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) agreed to acquire an additional 24.83% stake in Xinjiang Tianjiao Hongan Agricultural Technology Co., Ltd. from Xinjiang Longping Gaoke Hong'an Seed Industry Co., Ltd. for CNY 20 million.

Earnings released

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥16.99

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) cancelled the acquisition of 10% stake in Tengchong Kang’enpu Biological Materials Co., Ltd. from Zhu Jingbo, Chen Xin and Zhang Jiaqi.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite